370TiPA phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer. (23rd October 2018) - Hurvitz, S A; Galsky, M D; Shahidi, J; Zhang, G; Raza, S; Necchi, A